Histones: Controlling Tumor Signaling Circuitry
- PMID: 25177526
- PMCID: PMC4149316
- DOI: 10.4172/2157-2518.S5-001
Histones: Controlling Tumor Signaling Circuitry
Abstract
Epigenetic modifications constitute the next frontier in tumor biology research. Post-translation modification of histones dynamically influences gene expression independent of alterations to the DNA sequence. These mechanisms are often mediated by histone linkers or by proteins associated with the recruitment of DNA-binding proteins, HDAC I and II interacting proteins and transcriptional activators, coactivators or corepressors. Early evidence suggested that histones and their modifiers are involved in sophisticated processes that modulate tumor behavior and cellular phenotype. In this review, we discuss how recent discoveries about chromatin modifications, particularly histone acetylation, are shaping our knowledge of cell biology and our understanding of the molecular circuitry governing tumor progression and consider whether recent insights may extend to novel therapeutic approaches. Furthermore, we discuss the latest oncogenomic findings in Head and Neck Squamous Cell Carcinoma (HNSCC) from studies using Next Generation Sequencing (NGS) technology and highlight the impact of mutations identified in histones and their modifiers.
Keywords: Acetylation; Chromatin compaction; Genetic code; H3; H4; Histone modifications; Oral cancer; Whole genome sequencing.
Figures
Similar articles
-
NFκB mediates cisplatin resistance through histone modifications in head and neck squamous cell carcinoma (HNSCC).FEBS Open Bio. 2013 Dec 30;4:96-104. doi: 10.1016/j.fob.2013.12.003. eCollection 2014. FEBS Open Bio. 2013. PMID: 24490130 Free PMC article.
-
Histone modifications: Targeting head and neck cancer stem cells.World J Stem Cells. 2014 Nov 26;6(5):511-25. doi: 10.4252/wjsc.v6.i5.511. World J Stem Cells. 2014. PMID: 25426249 Free PMC article. Review.
-
Epigenetic Modifications and Head and Neck Cancer: Implications for Tumor Progression and Resistance to Therapy.Int J Mol Sci. 2017 Jul 12;18(7):1506. doi: 10.3390/ijms18071506. Int J Mol Sci. 2017. PMID: 28704968 Free PMC article. Review.
-
Inhibition of histone deacetylase impacts cancer stem cells and induces epithelial-mesenchyme transition of head and neck cancer.PLoS One. 2013;8(3):e58672. doi: 10.1371/journal.pone.0058672. Epub 2013 Mar 20. PLoS One. 2013. PMID: 23527004 Free PMC article.
-
Acetylation and methylation in nuclear receptor gene activation.Methods Enzymol. 2003;364:205-23. doi: 10.1016/s0076-6879(03)64012-7. Methods Enzymol. 2003. PMID: 14631847
Cited by
-
Targeting histone deacetylase and NFκB signaling as a novel therapy for Mucoepidermoid Carcinomas.Sci Rep. 2018 Feb 1;8(1):2065. doi: 10.1038/s41598-018-20345-w. Sci Rep. 2018. PMID: 29391537 Free PMC article.
-
Epigenetic Modifications and Accumulation of DNA Double-Strand Breaks in Oral Lichen Planus Lesions Presenting Poor Response to Therapy.Medicine (Baltimore). 2015 Jul;94(30):e997. doi: 10.1097/MD.0000000000000997. Medicine (Baltimore). 2015. PMID: 26222871 Free PMC article. Clinical Trial.
-
Photobiomodulation therapy modulates epigenetic events and NF-κB expression in oral epithelial wound healing.Lasers Med Sci. 2019 Sep;34(7):1465-1472. doi: 10.1007/s10103-019-02745-0. Epub 2019 Feb 28. Lasers Med Sci. 2019. PMID: 30820776
-
A Catalogue of Altered Salivary Proteins Secondary to Invasive Ductal Carcinoma: A Novel In Vivo Paradigm to Assess Breast Cancer Progression.Sci Rep. 2016 Aug 1;6:30800. doi: 10.1038/srep30800. Sci Rep. 2016. PMID: 27477923 Free PMC article. Clinical Trial.
-
A Mutation in Histone H2B Represents a New Class of Oncogenic Driver.Cancer Discov. 2019 Oct;9(10):1438-1451. doi: 10.1158/2159-8290.CD-19-0393. Epub 2019 Jul 23. Cancer Discov. 2019. PMID: 31337617 Free PMC article.
References
-
- van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415:530–536. - PubMed
-
- van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347:1999–2009. - PubMed
-
- Cedar H, Bergman Y. Linking DNA methylation and histone modification: patterns and paradigms. Nat Rev Genet. 2009;10:295–304. - PubMed
-
- Schafer S, Jung M. Chromatin modifications as targets for new anticancer drugs. Arch Pharm (Weinheim) 2005;338:347–357. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources